Role of ranolazine in heart failure: From cellular to clinic perspective.

Kaplan, Abdullah; Amin, Ghadir; Abidi, Emna; Altara, Raffaele; Booz, George W; Zouein, Fouad A

Kaplan, Abdullah; Amin, Ghadir; Abidi, Emna; Altara, Raffaele; Booz, George W; Zouein, Fouad A.

Afiliación

Kaplan A; Department of Pharmacology and Toxicology, American University of Beirut Faculty of Medicine, Beirut, Lebanon; Rumeli Hospital, Cardiology Clinic, Istanbul, Turkey. Electronic address: kaplanabd@gmail.com.
Amin G; Department of Pharmacology and Toxicology, American University of Beirut Faculty of Medicine, Beirut, Lebanon.
Abidi E; Department of Pharmacology and Toxicology, American University of Beirut Faculty of Medicine, Beirut, Lebanon.
Altara R; Department of Pathology, School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Booz GW; Department of Pharmacology and Toxicology, School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Zouein FA; Department of Pharmacology and Toxicology, American University of Beirut Faculty of Medicine, Beirut, Lebanon; Department of Pharmacology and Toxicology, School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA. Electronic address: fz15@aub.edu.lb.

Eur J Pharmacol ; 919: 174787, 2022 Mar 15.

Article en En | MEDLINE | ID: mdl-35114190

Asunto(s)

Insuficiencia Cardíaca/tratamiento farmacológico; Ranolazina/uso terapéutico; Bloqueadores de los Canales de Sodio/uso terapéutico; Humanos

Palabras clave

Angina; Cardiac remodeling; Heart failure; Late sodium current; Mitochondrial function; Na(+)-Ca(2+) exchanger (NCX)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Bloqueadores de los Canales de Sodio / Ranolazina / Insuficiencia Cardíaca Límite: Humans Idioma: En Revista: Eur J Pharmacol Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google